KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Treasury Shares (2018 - 2025)

Vir Biotechnology's Treasury Shares history spans 8 years, with the latest figure at $5.7 million for Q4 2025.

  • On a quarterly basis, Treasury Shares rose 14.23% to $5.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.7 million, a 14.23% increase, with the full-year FY2025 number at $5.7 million, up 14.23% from a year prior.
  • Treasury Shares hit $5.7 million in Q4 2025 for Vir Biotechnology, up from $5.0 million in the prior quarter.
  • Over the last five years, Treasury Shares for VIR hit a ceiling of $5.7 million in Q4 2025 and a floor of $36298.0 in Q1 2021.
  • Historically, Treasury Shares has averaged $2.9 million across 5 years, with a median of $2.7 million in 2022.
  • Biggest five-year swings in Treasury Shares: crashed 97.51% in 2021 and later skyrocketed 7452.44% in 2022.
  • Tracing VIR's Treasury Shares over 5 years: stood at $1.3 million in 2021, then surged by 109.84% to $2.7 million in 2022, then soared by 80.11% to $4.8 million in 2023, then grew by 3.67% to $5.0 million in 2024, then grew by 14.23% to $5.7 million in 2025.
  • Business Quant data shows Treasury Shares for VIR at $5.7 million in Q4 2025, $5.0 million in Q4 2024, and $4.8 million in Q4 2023.